US
CA
NZ
UK
AU
IND
Last update at 2025-06-16T14:51:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Fri 09 May 25, 01:40 PMLigand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Thu 07 Nov 24, 12:00 PMGSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
Wed 18 Sep 24, 11:00 AMLigand Reports Second Quarter 2024 Financial Results
Tue 06 Aug 24, 08:01 PMBristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
Mon 05 Aug 24, 06:31 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -230.65600M | -28.72400M | -182.89100M | -111.56000M | -162.04402M |
| Minority interest | -10.58200M | -4.79800M | -7.82600M | -3.90300M | -2.07800M |
| Net income | -271.51500M | -94.69600M | -240.13400M | -149.13600M | -159.69212M |
| Selling general administrative | 81.01M | 76.36M | 59.22M | 46.04M | 37.34M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | -99.23500M | 113.59M | -56.79600M | -18.29100M | -87.81681M |
| Reconciled depreciation | 6.95M | 6.79M | 7.18M | 6.66M | 6.29M |
| Ebit | -179.42700M | 42.28M | -117.23500M | -70.13700M | -127.33983M |
| Ebitda | -160.72500M | 49.07M | -110.69300M | -57.64200M | -121.05183M |
| Depreciation and amortization | 18.70M | 6.79M | 6.54M | 12.49M | 6.29M |
| Non operating income net other | 12.57M | 11.25M | -1.85800M | 0.03M | -12.94990M |
| Operating income | -179.42700M | 42.28M | -117.23500M | -70.13700M | -123.82156M |
| Other operating expenses | 278.27M | 258.44M | 204.18M | 214.38M | 161.94M |
| Interest expense | 61.86M | 65.72M | 61.08M | 41.45M | 25.27M |
| Tax provision | - | - | - | - | - |
| Interest income | - | - | - | 41.45M | 25.27M |
| Net interest income | -61.86300M | -65.71900M | -61.07800M | -41.45100M | -25.27256M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 40.86M | 65.97M | 57.24M | 37.58M | -12.94990M |
| Total revenue | 98.02M | 295.67M | 88.17M | 150.05M | 36.78M |
| Total operating expenses | 81.01M | 76.36M | 59.22M | 46.04M | 37.34M |
| Cost of revenue | 197.26M | 182.08M | 144.97M | 168.34M | 124.60M |
| Total other income expense net | -51.22900M | -71.00300M | -65.65600M | -41.42300M | -11.61490M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | -228.71900M | -28.72400M | -182.89100M | -111.56000M | -162.04402M |
| Net income applicable to common shares | -220.28600M | -24.13700M | -181.12300M | -107.86500M | -159.89900M |
| Preferred stock and other adjustments | 0.21M | 0.21M | 0.21M | 0.21M | 0.21M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 313.91M | 413.56M | 465.96M | 214.51M | 155.34M |
| Intangible assets | 4.41M | 6.23M | 8.49M | 10.89M | 10.50M |
| Earning assets | - | - | - | - | - |
| Other current assets | 10.47M | 3.19M | 3.17M | 2.01M | 1.01M |
| Total liab | 462.30M | 468.46M | 418.05M | 426.01M | 386.67M |
| Total stockholder equity | -160.33100M | -61.27800M | 34.44M | -203.67200M | -225.35600M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 48.74M | 133.23M | 110.68M | 92.90M | 77.48M |
| Common stock | 3.94M | 3.06M | 2.57M | 1.96M | 1.38M |
| Capital stock | 3.94M | 3.06M | 2.57M | 1.96M | 1.38M |
| Retained earnings | -1955.66800M | -1709.90700M | -1489.83300M | -1465.90700M | -1284.99300M |
| Other liab | - | 191.33M | 205.86M | 216.20M | 216.15M |
| Good will | 24.72M | 25.47M | 24.88M | 25.45M | 23.19M |
| Other assets | - | 4.45M | 9.54M | 37.60M | 1.42M |
| Cash | 76.11M | 178.67M | 291.93M | 99.87M | 61.81M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 255.90M | 188.95M | 156.94M | 129.88M | 122.21M |
| Current deferred revenue | 0.02M | 12.27M | 12.43M | 17.19M | 29.17M |
| Net debt | 274.14M | -100.24600M | -233.64400M | -44.14400M | -38.41500M |
| Short term debt | 145.69M | 2.52M | 3.35M | 2.78M | 1.99M |
| Short long term debt | 0.15M | 0.57M | 0.73M | 0.83M | 0.65M |
| Short long term debt total | 350.25M | 78.43M | 58.29M | 55.73M | 23.39M |
| Other stockholder equity | 1478.43M | 1231.10M | 1054.25M | 1230.59M | 1032.67M |
| Property plant equipment | - | 133.02M | 91.08M | 60.27M | 26.33M |
| Total current assets | 112.42M | 213.12M | 331.97M | 113.78M | 86.54M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 159.25M | 1.08M | -240.01000M | -20.99800M |
| Short term investments | 0.00000M | 14.68M | 14.99M | - | - |
| Net receivables | 25.84M | 2.74M | 1.52M | 1.16M | 16.29M |
| Long term debt | 12.77M | 12.58M | 12.82M | 18.88M | 13.38M |
| Inventory | 0.00000M | 13.83M | 20.36M | 10.75M | 7.42M |
| Accounts payable | 61.45M | 40.94M | 30.49M | 17.02M | 13.56M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | 6.38M | 13.47M | -7.82600M | -5.98100M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.95500M | 0.92M | 1.49M | 2.77M | -1.32400M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 3.06M | 2.57M | 1.96M | 1.38M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -1709.90700M | -1489.83300M | -1465.90700M | -1284.99300M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5.67M | 4.45M | 9.54M | 4.12M | 1.42M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 201.50M | 200.43M | 133.98M | 100.73M | 68.80M |
| Capital lease obligations | 65.10M | 65.27M | 44.74M | 36.02M | 9.37M |
| Long term debt total | - | 12.58M | 12.82M | 18.88M | 13.38M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.37M | -14.99200M | -4.44100M | -4.65700M | -3.59092M |
| Change to liabilities | 8.53M | -11.00800M | -8.69700M | 6.86M | 8.67M |
| Total cashflows from investing activities | -33.61000M | -43.15000M | -4.44100M | -4.65700M | -3.59092M |
| Net borrowings | -0.49000M | -1.31700M | 2.96M | -0.32000M | -162.13063M |
| Total cash from financing activities | 95.83M | 225.26M | 183.85M | 31.32M | 128.28M |
| Change to operating activities | 27.84M | 1.66M | 1.46M | 20.32M | -5.02000M |
| Net income | -230.65600M | -28.72400M | -182.89100M | -111.56000M | -162.04402M |
| Change in cash | -113.25700M | 192.09M | 40.70M | 8.75M | -7.13309M |
| Begin period cash flow | 294.60M | 102.50M | 61.81M | 53.05M | 60.19M |
| End period cash flow | 181.34M | 294.60M | 102.50M | 61.81M | 53.05M |
| Total cash from operating activities | -175.37300M | 10.14M | -139.09600M | -18.68200M | -131.09452M |
| Issuance of capital stock | 99.21M | 220.65M | 176.42M | 30.00M | 84.80M |
| Depreciation | 6.95M | 6.79M | 7.18M | 6.66M | 6.29M |
| Other cashflows from investing activities | 19.08M | 5.66M | -0.97500M | - | 0.00619M |
| Dividends paid | - | -9.13200M | - | - | 0.00000M |
| Change to inventory | - | -6.19100M | 3.64M | 0.06M | 0.02M |
| Change to account receivables | 0.12M | -0.39400M | 16.19M | -15.35500M | 0.20M |
| Sale purchase of stock | -3.78900M | -1.65400M | 176.42M | 30.00M | 86.03M |
| Other cashflows from financing activities | 0.90M | 16.72M | 10.67M | 1.64M | 245.50M |
| Change to netincome | 70.39M | 37.03M | 25.68M | 57.96M | 41.80M |
| Capital expenditures | 53.06M | 33.81M | 3.47M | 4.66M | 3.60M |
| Change receivables | 0.12M | -0.39400M | 16.19M | -15.35500M | 0.20M |
| Cash flows other operating | -30.70500M | -63.46600M | -58.02900M | 36.70M | -26.02945M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -113.15300M | 192.26M | 40.32M | 7.98M | -6.40052M |
| Change in working capital | 24.08M | -9.74300M | 8.95M | 58.68M | 0.17M |
| Stock based compensation | 18.34M | 19.58M | 10.42M | 9.89M | 7.63M |
| Other non cash items | 5.92M | 31.75M | 14.33M | 17.58M | 5.95M |
| Free cash flow | -228.43500M | -23.66900M | -142.56200M | -23.33900M | -134.69162M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AGEN Agenus Inc |
0.19 4.00% | 4.89 | 1.17 | - | 1.09 | 218.62 | 1.10 | -1.1829 |
| NVO Novo Nordisk A/S |
-2.25 2.82% | 77.58 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.25 1.54% | 79.75 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.04 0.45% | 453.41 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
6.40 1.21% | 535.64 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
3 Forbes Road, Lexington, MA, United States, 02421-7305
| Name | Title | Year Born |
|---|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Exec. Chairman & CEO | 1953 |
| Ms. Christine M. Klaskin | VP of Fin., Principal Financial Officer & Principal Accounting Officer | 1966 |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer | 1962 |
| Dr. Jennifer S. Buell Ph.D. | Pres & CEO of MiNK Therapeutics | 1975 |
| Craig Winter | Chief Information Officer | NA |
| Regina Grebla Ph.D. | VP of Investor Relations & Communications | NA |
| Ms. Robin E. Abrams J.D. | Chief Legal Officer | 1964 |
| Ms. Tracy Mazza Clemente | Chief People Officer | NA |
| John Castle | Head of Translational Medicine & Bioinformatics | NA |
| Ms. Julie DeSander | Chief Bus. Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...